Skip to main content
OpenTrials
Completed

NCT Number: NCT03808272

AXIOS CHINA (E7148)

To study the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic trans enteric drainage of pancreatic pseudocyst and walled-off necrosis in Chinese population, to support the regulatory approval by CFDA

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 100000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years old(including 18 and 75 years old)
  • Eligible for endoscopic intervention
  • Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage
  • Diagnostic as symptomatic pancreatic pseudocysts ≥ 6cm in maximum diameter and walled-off necrosis ≥ 6cm in maximum diameter with ≥ 70% fluid content that are adherent to the gastric or bowel wall
  • Patient understands the study requirements and the treatment procedures and provides written Informed Consent.
  • Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post CT imaging study.

Exclusion criteria

  • <18 or >75 years of age
  • pseudocysts or walled-off necrosis which require nasocystic drainage,or<6cm in maximum diameter, or walled-off necrosis < 70% fluid content
  • The fluid collection to be drained is an immature pseudocyst
  • The fluid collection to be drained is a cystic neoplasm
  • The fluid collection to be drained is a pseudoaneurysm
  • The fluid collection to be drained is a duplication cyst
  • The fluid collection to be drained is a non-inflammatory fluid collection
  • There is more than one pseudocyst requiring drainage
  • Abnormal coagulation: INR > 1.5 and not correctable presence of a bleeding disorder; platelets < 50,000/mm3
  • Altered anatomy that precludes the physician's ability to deliver the stent (decision on a case by case basis).
  • Intervening gastric varices or vessels within a one centimeter radius of the needle (visible using endoscopy or endoscopic ultrasound)
  • Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient.
  • Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study.
  • Currently participating in another investigational drug of device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.

Treatment and study plan

HOT AXIOS Stent and Electrocautery- Enhanced Delivery System

Device

The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.

Primary outcomes

  1. Technical success rate

    Time frame: 28± 7 days post stent placement

    defined as: placement of the AXIOS stent using the Electrocautery Enhanced AXIOS delivery system and removal of the AXIOS stent using a standard method: such as endoscopic snare or forceps.

  2. Clinical success rate

    Time frame: 28± 7 days post stent placement

    defined as: at least a 50% decrease in pseudocyst's maximum diameter, based on radiographic analysis

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

A Prospective, Multi-center, Single-arm Study to Evaluate the Safety and Efficacy of AXIOS Stent and Electrocautery-enhanced Delivery System in Chinese Patients With Pancreatic Pseudocyst and Walled-off Necrosis(WON)

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jan 17, 2019
Registry last updated
Nov 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.